WASHINGTON, April 30, 2009 (GLOBE NEWSWIRE) -- The law firm of Finkelstein Thompson LLC is currently investigating potential legal claims on behalf of shareholders of Sequenom, Inc. (Nasdaq:SQNM) ("Sequenom") in connection with recent news concerning the company's clinical studies of its prenatal genetic test for Down syndrome. Finkelstein Thompson LLC welcomes inquiries from Sequenom shareholders by phone at (877) 337-1050 or by email at contact@finkelsteinthompson.com.
News reports indicate that Sequenom publicized clinical data throughout 2008 and 2009, which it claimed confirmed the strong efficacy of Sequenom's prenatal genetic test for Down syndrome. On April 29, 2009, Sequenom disclosed "employee mishandling" of the clinical data, which raised "significant concerns regarding the integrity of that data." Sequenom further disclosed that it no longer intends to rely on the previously disclosed data. In the first hour of trading after this revelation, Sequenom shares plunged 77%, or $11.43, to $3.48 on 27 times its average daily volume over the past 30 days.
Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in connection with securities and other finance-related litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. To learn more about Finkelstein Thompson LLP, please visit www.finkelsteinthompson.com.